Humanized mice in Immuno-Oncology : A game-changer for preclinical research
Autors:
Caroline Mignard, Charlotte Dejucq, Estelle Verronese, Damien France, Vincent Faugeroux, Emilie Heckel
Oncodesign Services
Abstract :
Immune cells within the tumor microenvironment are now well recognized as to be targets of interest for cancer treatment. Many findings from conventional animal models do not apply to humans due to the intrinsic differences between species. This fact would explain the large need for humanized mouse models that will accurately support the pre-clinical development of such therapeutic approaches.
Human immune system should be reconstituted in immunodeficient mice using either human PBMCs or hematopoietic stem cells (HSCs). So called “Humanized” mouse models, have been established to study the complex interaction of the human immune system during human disorders, when the syngeneic mouse model cannot constitute the test model. Humanized immunodeficient mice, bearing human immune cells with human target tumor cells, are relevant models to test various therapeutic strategies (e.g. adoptive cell transfer, immune checkpoint inhibitors, oncolytic virus…) in oncology.
Growth characteristics of human tumors models on humanized mice will be presented either as subcutaneous (tumor cell line and Patient Derived Xenograft) or as disseminated intravenous model. Randomization parameters were selected regarding both tumor and immune cell sides. Required readouts to understand immune cell modulation and related antitumor efficacy will be described.
The poster will include illustrative data and case study examples highlighting the platform and how these models are used in preclinical studies for evaluation of drug candidates in immune-oncology.
